Abstract
In drug eluting stent technologies, an increased demand for better control, higher reliability and enhanced performances of drug delivery systems emerged in the last years and thus offered the opportunity to introduce model-based approaches aimed to overcome the remarkable limits of trial–and-error methods. In this context a chemical engineering approach was studied, being based on the detailed conservation equations and taking into account the main physical–chemical mechanisms involved in polymeric coating degradation, drug release and restenosis inhibition. It allowed highlighting the interdependence between factors affecting each of these phenomena and, in particular, the influences of stent design parameters on drug antirestenotic efficacy. The hierarchical structure of this model also allows easily modifying the set of equations describing restenosis evolution in order to enhance model reliability and taking advantage of the deep understanding of physiological mechanisms governing the different stages of smooth muscle cell growth and proliferation. In addition, thanks to its simplicity and to the very low system requirements and CPU time, our model allows obtaining immediate views of system behavior.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bagust, A., Grayson, A. D., Palmer, N. D., Perry, R. A., & Walley, T. (2006). Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study. Heart, 92, 68–74.
Dawkins, K. D., Grube, E., Guagliumi, G., Banning, A. P., Zmudka, K., Colombo, A., et al. (2005). Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial—Support for the use of drug-eluting Stents in contemporary clinical practice. Circulation, 112, 3306–3313.
Finkelstein, A., McClean, D., Kar, S., Takizawa, K., Varghese, K., Baek, N., et al. (2003). Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation, 107, 777–784.
Franks, S. J., Byrne, H. M., King, J. R., Underwood, J. C. E., & Lewis, C. E. (2003a). Modelling the early growth of ductal carcinoma in situ of the breast. Journal of Mathematical Biology, 47, 424–452.
Franks, S. J., Byrne, H. M., King, J. R., Underwood, J. C. E., & Lewis, C. E. (2003b). Modelling the early growth of ductal carcinoma in situ of the breast. Journal of Mathematical Biology, 47, 424–452.
Kastrati, A., Dibra, A., Eberle, S., Mehilli, J., de Lezo, J. S., Goy, J. J., et al. (2005). Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease—Meta-analysis of randomized trials. JAMA, 294, 819–825.
Lemos, P. A., Serruys, P. W., & Sousa J. E. (2003). Drug-eluting stents. Cost vs clinical benefit. Circulation, 107, 3003–3007.
Levin, A. D., Vukmirovic, N., Hwang, C. W., & Edelman, E. R. (2004). Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc. Natl Acad. Sci. U S A, 101, 9463–9467.
McFadden, E. P., Stabile, E., Regar, E., Cheneau, E., Ong, A. T. L., Kinnaird, T., et al. (2004). Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet, 364, 1519–1521.
Ong, A. T. L., Serruys, P. W., Aoki, J., Hoye, A., van Mieghem, C. A. G., Rodriguez-Granillo, G. A., et al. (2005). The unrestricted use of paclitaxel-versus sirolimus-eluting stents for coronary artery disease in an unselected population—One-year results of the Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) registry. Journal of the American College of Cardiology, 45, 1135–1141.
Scheller, B., Speck, U., Schmitt, A., Bohm, M., & Nickenig, G. (2003). Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. Journal of the American College of Cardiology, 42, 1415–1420.
Schwartz, R. S., Chronos, N. A., & Virmani, R. (2004). Preclinical restenosis models and drug-eluting stents - Still important, still much to learn. Journal of the American College of Cardiology, 44, 1373–1385.
Serruys PW and Gershlick A (2005) In Handbook of Drug-Eluting Stents. Vol. pp. CRC Press, New York,
Sousa, J. E., Costa, M. A., Abizaid, A., Abizaid, A. S., Feres, F., Pinto, I. M. F., et al. (2001). Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries—A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation, 103, 192–195.
Sousa, J. E., Serruys, P. W., & Costa, M. A. (2003). New frontiers in cardiology—Drug-eluting stents: Part II. Circulation, 107, 2383–2389.
Steigerwald, K., Merl, S., Kastrati, A., Wieczorek, A., Vorpahl, M., Mannhold, R., et al. (2009). The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts. Biomaterials, 30, 632–637.
Stone, G. W., Ellis, S. G., Cox, D. A., Hermiller, J., O’Shaughnessy, C., Mann, J. T., et al. (2004a). One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS Stent the TAXUS-IV trial. Circulation, 109, 1942–1947.
Stone, G. W., Ellis, S. G., Cox, D. A., Hermiller, J., O’Shaughnessy, C., Mann, J. T., et al. (2004b). A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. New England Journal of Medicine, 350, 221–231.
Tanimoto, S., Daemen, J., Tsuchida, K., Garcia-Garcia, H. M., de Jaegere, P., van Dornburg, R. T., et al. (2007). Two-year clinical outcome after coronary stenting of small vessels using 2.25-mm sirolimus- and paclitaxel-eluting stents: Insight into the RESEARCH and T-SEARCH registries. Catheterization and Cardiovascular Interventions, 69, 94–103.
Togni, M., Eber, S., Widmer, J., Billinger, M., Wenaweser, P., Cook, S., et al. (2007). Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents—A subgroup analysis of the SIRTAX trial. Journal of the American College of Cardiology, 50, 1123–1131.
Venkatraman, S., & Boey, F. (2007). Release profiles in drug-eluting stents: Issues and uncertainties. J. Control. Release, 120, 149–160.
Virmani, R., Guagliumi, G., Farb, A., Musumeci, G., Grieco, N., Motta, T., et al. (2004). Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent should we be cautious? Circulation, 109, 701–705.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2016 The Author(s)
About this chapter
Cite this chapter
Rossi, F., Perale, G., Masi, M. (2016). Case Study: Drug Eluting Stent. In: Controlled Drug Delivery Systems. SpringerBriefs in Applied Sciences and Technology(). Springer, Cham. https://doi.org/10.1007/978-3-319-02288-8_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-02288-8_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-02287-1
Online ISBN: 978-3-319-02288-8
eBook Packages: EngineeringEngineering (R0)